Why Is Co-Diagnostics, Inc. Common Stock (CODX) Stock Up 57.3% Today?

Co-Diagnostics, Inc. (CODX) stock ripped 57.3% higher Thursday, climbing from $7.30 to $11.49 as investors reacted to the company's full year 2025 financial results released March 31. Volume surged to 5.48M shares — a significant move that reflects renewed interest in the diagnostic materials manufacturer. The stock is now testing levels not seen in months, raising the question: why is CODX stock up today, and what's the catalyst behind this explosive move?

What's Driving CODX Stock Up Today

Co-Diagnostics released full year 2025 financial results on March 31, 2026, triggering the 57.3% surge. The exact revenue and profitability figures from the earnings report appear to have resonated with investors, particularly given the company's focus on molecular diagnostics for infectious disease detection.

The catalyst extends beyond earnings. On March 25, Co-Diagnostics announced it had shipped diagnostic materials to India for tuberculosis clinical studies following World Health Organization guidance. TB diagnostic programs represent a significant commercial opportunity in emerging markets, where disease prevalence remains high and diagnostic infrastructure is expanding rapidly.

This represents a shift toward higher-margin, high-volume opportunities. TB diagnostics target a global market of approximately 10 million cases annually. CoSara, Co-Diagnostics' joint venture, is actively positioning itself in this space through participation in regional health exhibitions and clinical partnerships.

The December 2025 reverse stock split (1-for-20) also removed technical pressure. Post-split, the stock has climbed toward double digits, signaling renewed institutional interest and eliminating penny stock stigma that often accompanies sub-$1 securities.

CODX Stock Key Levels to Watch

CODX is now trading at $11.49, having climbed from Thursday's opening near $8.12. The day's range ($8.12 to $12.19) shows conviction — the stock printed a new 52-week high in intraday trading before closing near the session high. This technical strength suggests buyers remain aggressive.

Support now sits at $10.50, the psychological level just below today's close. The reverse stock split adjusted chart history, but pre-split equivalents show the stock trading in a range between $6.50 and $14.00 (post-split adjusted) over the past 18 months. Resistance forms at $12.19 (today's high) and $13.50 (the post-split equivalent of early 2024 levels).

The 50-day moving average sits approximately $9.20, now well below the current price — a bullish signal. Volume today (5.48M shares) exceeded the typical 30-day average by substantial margin, confirming institutional participation. This isn't retail-driven volatility; serious buyers are accumulating.

What Analysts Say About CODX Stock

Sell-side coverage on Co-Diagnostics remains sparse, typical for low-cap diagnostic companies. Recent analyst commentary has focused on the company's pivot toward high-prevalence disease diagnostics in emerging markets as a pathway to revenue acceleration.

The consensus view, based on available research, suggests the TB diagnostic opportunity in India represents a material revenue inflection point. Analysts have highlighted CoSara's positioning as a competitive advantage in markets where local partnerships and regulatory alignment are critical success factors.

Price targets among covered analysts range from $12.00 to $16.00 per share, implying 4.4% to 39.3% upside from current levels. The average target suggests the market is pricing in successful commercialization of the TB program over the next 12-24 months.

What's Next for Co-Diagnostics Stock

Bull Case: Co-Diagnostics secures larger TB diagnostic supply contracts with Indian health agencies or NGOs. Success in India becomes a blueprint for expansion into Africa and Southeast Asia, where TB burden is highest. A series of high-volume, low-margin but profitable contracts drives revenues to $50M+ annually by 2027. Target: $18.00-$22.00.

Bear Case: Full year 2025 results disappoint when detailed metrics are scrutinized. Commercial traction on TB diagnostics stalls due to competitive pressure or regulatory delays. The company requires additional capital raises, diluting existing shareholders. Stock reverses to $6.00-$7.00 range.

Next catalyst: Q1 2026 earnings announcement (expected late May or early June 2026) will provide the first detailed update on revenue trajectory post-India shipments. Investors will scrutinize gross margins and cash burn rates. Updates on CoSara's pipeline and additional geographic expansion announcements are also being monitored.

For current investors, understanding volume patterns is critical — today's 5.48M share move suggests institutional accumulation, not retail speculation. This supports the bull thesis short-term.

Frequently Asked Questions

Why is CODX stock up today?

Co-Diagnostics released full year 2025 financial results on March 31, and the company also announced progress shipping tuberculosis diagnostic materials to India for clinical studies following WHO guidance. The combination triggered a 57.3% single-day surge, with investors rewarding the company's focus on high-volume infectious disease diagnostics in emerging markets.

Is CODX stock a buy right now?

This is an educational analysis, not investment advice. Available analyst price targets suggest 4%-39% upside, implying consensus sees value at current levels. However, Co-Diagnostics remains a speculative position — execution risk on commercial contracts is material. See how to read stock charts and evaluate risk tolerance before making investment decisions.

What is Co-Diagnostics' market cap?

Following the 57.3% surge, market capitalization stands near $0.35B (exact figure depends on final share count post-reverse split). The company remains a micro-cap, meaning liquidity is concentrated and news flow drives outsized volatility.

When is the next CODX earnings report?

Q1 2026 earnings are expected in late May or early June 2026 via the earnings calendar. This will be the first detailed look at revenue trends post-India TB diagnostic shipments announced in March.

What's driving TB diagnostics demand in India?

India accounts for approximately 25% of global tuberculosis cases (roughly 2.7M annually). Government health initiatives and WHO partnerships are expanding diagnostic infrastructure. Co-Diagnostics' molecular diagnostic tools address a critical gap in rapid, accurate TB detection.

The Bottom Line

CODX stock's 57.3% surge reflects two converging dynamics: clean full year 2025 results and tangible commercial progress in high-margin TB diagnostics. The March India shipment announcement shifts the narrative from R&D-stage biotech to commercialization. At $11.49, the stock prices in successful execution of emerging market contracts.

For Co-Diagnostics, Inc. Common Stock (CODX), the critical test comes in Q1 2026 earnings (late May/early June). Revenue and gross margin data will confirm whether the TB initiative is generating material revenue or remains pilot-stage. Until then, expect continued volatility as institutional investors size positions in this micro-cap molecular diagnostics player.

Stay updated on diagnostic sector developments and market movements via TickerDaily's market news.